These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

316 related items for PubMed ID: 34418398

  • 21. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.
    Lublin F, Miller DH, Freedman MS, Cree BAC, Wolinsky JS, Weiner H, Lubetzki C, Hartung HP, Montalban X, Uitdehaag BMJ, Merschhemke M, Li B, Putzki N, Liu FC, Häring DA, Kappos L, INFORMS study investigators.
    Lancet; 2016 Mar 12; 387(10023):1075-1084. PubMed ID: 26827074
    [Abstract] [Full Text] [Related]

  • 22. Bexarotene leads to durable improvements in visual evoked potential latency: A follow-up study of the Cambridge Centre for Myelin Repair One trial.
    McMurran CE, Mukherjee T, Brown JWL, Coles AJ, Cunniffe NG.
    Mult Scler; 2024 Jul 12; 30(8):1066-1071. PubMed ID: 38426437
    [Abstract] [Full Text] [Related]

  • 23. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.
    Wolinsky JS, Arnold DL, Brochet B, Hartung HP, Montalban X, Naismith RT, Manfrini M, Overell J, Koendgen H, Sauter A, Bennett I, Hubeaux S, Kappos L, Hauser SL.
    Lancet Neurol; 2020 Dec 12; 19(12):998-1009. PubMed ID: 33129442
    [Abstract] [Full Text] [Related]

  • 24. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.
    Kappos L, Li D, Calabresi PA, O'Connor P, Bar-Or A, Barkhof F, Yin M, Leppert D, Glanzman R, Tinbergen J, Hauser SL.
    Lancet; 2011 Nov 19; 378(9805):1779-87. PubMed ID: 22047971
    [Abstract] [Full Text] [Related]

  • 25. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ, Figgitt DP.
    CNS Drugs; 2004 Nov 19; 18(6):379-96. PubMed ID: 15089110
    [Abstract] [Full Text] [Related]

  • 26. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K, Williams J, Qi YP, Gutman J, Yeung L, Mai C, Finkelstain J, Mehta S, Pons-Duran C, Menéndez C, Moraleda C, Rogers L, Daniels K, Green P.
    Cochrane Database Syst Rev; 2022 Feb 01; 2(2022):. PubMed ID: 36321557
    [Abstract] [Full Text] [Related]

  • 27. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.
    Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V, Polman CH, Schmierer K, Yousry TA, Yang M, Eraksoy M, Meluzinova E, Rektor I, Dawson KT, Sandrock AW, O'Neill GN, BG-12 Phase IIb Study Investigators.
    Lancet; 2008 Oct 25; 372(9648):1463-72. PubMed ID: 18970976
    [Abstract] [Full Text] [Related]

  • 28. Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials.
    Montalban X, Vermersch P, Arnold DL, Bar-Or A, Cree BAC, Cross AH, Kubala Havrdova E, Kappos L, Stuve O, Wiendl H, Wolinsky JS, Dahlke F, Le Bolay C, Shen Loo L, Gopalakrishnan S, Hyvert Y, Javor A, Guehring H, Tenenbaum N, Tomic D, evolutionRMS investigators.
    Lancet Neurol; 2024 Nov 25; 23(11):1119-1132. PubMed ID: 39307151
    [Abstract] [Full Text] [Related]

  • 29. Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial.
    Zajicek J, Ball S, Wright D, Vickery J, Nunn A, Miller D, Cano MG, McManus D, Mallik S, Hobart J, CUPID investigator group.
    Lancet Neurol; 2013 Sep 25; 12(9):857-865. PubMed ID: 23856559
    [Abstract] [Full Text] [Related]

  • 30. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.
    Ambery P, Parker VE, Stumvoll M, Posch MG, Heise T, Plum-Moerschel L, Tsai LF, Robertson D, Jain M, Petrone M, Rondinone C, Hirshberg B, Jermutus L.
    Lancet; 2018 Jun 30; 391(10140):2607-2618. PubMed ID: 29945727
    [Abstract] [Full Text] [Related]

  • 31. Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial.
    Nourbakhsh B, Revirajan N, Morris B, Cordano C, Creasman J, Manguinao M, Krysko K, Rutatangwa A, Auvray C, Aljarallah S, Jin C, Mowry E, McCulloch C, Waubant E.
    Lancet Neurol; 2021 Jan 30; 20(1):38-48. PubMed ID: 33242419
    [Abstract] [Full Text] [Related]

  • 32. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
    Writing Group, Edaravone (MCI-186) ALS 19 Study Group.
    Lancet Neurol; 2017 Jul 30; 16(7):505-512. PubMed ID: 28522181
    [Abstract] [Full Text] [Related]

  • 33. Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial.
    Raftopoulos R, Hickman SJ, Toosy A, Sharrack B, Mallik S, Paling D, Altmann DR, Yiannakas MC, Malladi P, Sheridan R, Sarrigiannis PG, Hoggard N, Koltzenburg M, Gandini Wheeler-Kingshott CA, Schmierer K, Giovannoni G, Miller DH, Kapoor R.
    Lancet Neurol; 2016 Mar 30; 15(3):259-69. PubMed ID: 26822749
    [Abstract] [Full Text] [Related]

  • 34. Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial.
    Cadavid D, Balcer L, Galetta S, Aktas O, Ziemssen T, Vanopdenbosch L, Frederiksen J, Skeen M, Jaffe GJ, Butzkueven H, Ziemssen F, Massacesi L, Chai Y, Xu L, Freeman S, RENEW Study Investigators.
    Lancet Neurol; 2017 Mar 30; 16(3):189-199. PubMed ID: 28229892
    [Abstract] [Full Text] [Related]

  • 35. Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial.
    Miller DH, Weber T, Grove R, Wardell C, Horrigan J, Graff O, Atkinson G, Dua P, Yousry T, Macmanus D, Montalban X.
    Lancet Neurol; 2012 Feb 30; 11(2):131-9. PubMed ID: 22226929
    [Abstract] [Full Text] [Related]

  • 36. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.
    Comi G, Pulizzi A, Rovaris M, Abramsky O, Arbizu T, Boiko A, Gold R, Havrdova E, Komoly S, Selmaj K, Sharrack B, Filippi M, LAQ/5062 Study Group.
    Lancet; 2008 Jun 21; 371(9630):2085-92. PubMed ID: 18572078
    [Abstract] [Full Text] [Related]

  • 37. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
    Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, Axmann J, Kirchgaessler KU, Samara K, Gilberg F, Cottin V.
    Lancet Respir Med; 2020 Feb 21; 8(2):147-157. PubMed ID: 31578169
    [Abstract] [Full Text] [Related]

  • 38. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial.
    Tahara M, Oeda T, Okada K, Kiriyama T, Ochi K, Maruyama H, Fukaura H, Nomura K, Shimizu Y, Mori M, Nakashima I, Misu T, Umemura A, Yamamoto K, Sawada H.
    Lancet Neurol; 2020 Apr 21; 19(4):298-306. PubMed ID: 32199095
    [Abstract] [Full Text] [Related]

  • 39. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial.
    Giovannoni G, Gold R, Selmaj K, Havrdova E, Montalban X, Radue EW, Stefoski D, McNeill M, Amaravadi L, Sweetser M, Elkins J, O'Neill G, SELECTION Study Investigators.
    Lancet Neurol; 2014 May 21; 13(5):472-81. PubMed ID: 24656609
    [Abstract] [Full Text] [Related]

  • 40. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study.
    Segal BM, Constantinescu CS, Raychaudhuri A, Kim L, Fidelus-Gort R, Kasper LH, Ustekinumab MS Investigators.
    Lancet Neurol; 2008 Sep 21; 7(9):796-804. PubMed ID: 18703004
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.